Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is the bioequivalent to the reference listed drug (RLD) Halaven® Injection of Eisai, Inc.
Eribulin Mesylate Injection is indicated for the treatment of adults with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease and unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.
Eribulin Mesylate Injection (RLD Halaven®) had estimated annual sales of USD 43.7 million in the U.S. (IQVIA MAT April 2026).
Safe Harbor Statement
All brand names and trademarks are the property of their respective owners
